% | $
Quotes you view appear here for quick access.

AVEO Pharmaceuticals, Inc. Message Board

  • taexpert928 taexpert928 May 23, 2013 8:04 PM Flag

    50% of biotech companies are trading below cash value. Cash burning is the reason

    Astellas does not intend to fund any future studies of tivozanib, in renal cell cancer. There are 2 options:

    1) AVEO continues alone a new P3 for RCC thus causing a huge cash burn

    2) AVEO terminates the TIVO study for RCC and as a result does not have anymore a potential important drug , Without any potential important drug , its market cap should be much less than $70M.

0.8899+0.0099(+1.13%)Sep 29 4:00 PMEDT